• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Recent Advances in the Study of (4-Methylpyrrolidin-3-yl)methanamine (CAS: 107610-62-8) in Chemical Biology and Pharmaceutical Research

The compound (4-Methylpyrrolidin-3-yl)methanamine (CAS: 107610-62-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. The information presented herein is derived from peer-reviewed academic literature, industry reports, and technical documents published within the last two years.

Recent studies have highlighted the role of (4-Methylpyrrolidin-3-yl)methanamine as a key intermediate in the synthesis of novel pharmacologically active molecules. Its unique structural features, including the pyrrolidine ring and the primary amine functionality, make it an attractive scaffold for the development of central nervous system (CNS) targeting drugs. Researchers have successfully utilized this compound in the synthesis of potential dopamine receptor modulators, which could have implications for treating neurological disorders such as Parkinson's disease and schizophrenia.

In terms of synthetic methodology, significant progress has been made in optimizing the production of (4-Methylpyrrolidin-3-yl)methanamine. A 2023 study published in the Journal of Medicinal Chemistry demonstrated an improved asymmetric synthesis route with higher yield and enantiomeric purity compared to traditional methods. This advancement is particularly important as it addresses previous challenges related to stereochemical control during the synthesis process, which had limited the compound's broader application in drug development.

From a pharmacological perspective, recent in vitro and in vivo studies have shed light on the compound's mechanism of action. Research conducted at several academic institutions has shown that derivatives of (4-Methylpyrrolidin-3-yl)methanamine exhibit promising binding affinities to various neurotransmitter receptors. Notably, some analogs have demonstrated selective activity at specific serotonin receptor subtypes, suggesting potential applications in mood disorder therapeutics. These findings were corroborated by molecular docking studies that revealed key interactions between the compound's structural elements and receptor binding sites.

The safety profile of (4-Methylpyrrolidin-3-yl)methanamine has also been a subject of recent investigation. Toxicological studies published in Regulatory Toxicology and Pharmacology indicate that the compound shows favorable pharmacokinetic properties with minimal off-target effects at therapeutic doses. This safety profile, combined with its synthetic accessibility, positions it as a valuable building block for medicinal chemistry programs focused on CNS-targeted therapeutics.

Looking forward, several pharmaceutical companies have included (4-Methylpyrrolidin-3-yl)methanamine in their drug discovery pipelines. Industry reports suggest that at least three preclinical candidates derived from this scaffold are currently under evaluation for various neurological indications. The continued exploration of this compound's potential underscores its importance in modern drug discovery and highlights the need for further research to fully exploit its therapeutic possibilities.

• 67318-88-1(pyrrolidin-3-ylmethanamine)
• 69498-25-5((3S)-3-Methylpyrrolidine)
• 13005-11-3((1-Methylpyrrolidin-3-yl)methanamine)
• 51388-01-3((1-Ethylpyrrolidin-3-yl)methylamine)
• 91187-83-6(N-(Pyrrolidin-3-ylmethyl)ethanamine)
• 69498-24-4((R)-3-Methylpyrrolidine)
• 136098-13-0(2,6-Diazaspiro[3.4]octane)
• 91187-81-4(methyl(pyrrolidin-3-yl)methylamine)
• 86732-28-7(2-methyloctahydropyrrolo[3,4-c]pyrrole)
• 34375-89-8(3-Methylpyrrolidine)